Antiretroviral analytical treatment interruption (ATI) to assess immunologic and virologic responses in participants who initiated ART in early HIV infection after having received VRC01 or placebo in HVTN 703/HPTN 081.
We are looking at the effect previous exposure to monoclonal antibodies and rapid ARV introduction will have on subsequent ability to suppress HIV viral load. This study is a follow on from the AMP study which was a proof of concept study in using monoclonal antibodies to prevent HIV acquisition.
Latest Update: 18 February 2021
For more about HVTN805/HPTN093 please email firstname.lastname@example.org